07:00 , Aug 11, 2016 |  BC Extra  |  Financial News

Metabolon raises $15M in series E

Metabolon Inc. (Durham, N.C.) raised a $15 million series E round. Metabolon said the round's sole investor, Essex Woodlands, may invest an additional $10 million, which Metabolon would use to buy back shares from existing...
01:15 , Nov 3, 2015 |  BC Extra  |  Company News

BMS acquires Cardioxyl

Bristol-Myers Squibb Co. (NYSE:BMY) will acquire Cardioxyl Pharmaceuticals Inc. (Chapel Hill, N.C.), which is developing cardiovascular therapies including lead candidate CXL-1427 . The second-generation prodrug of nitroxyl (HNO) is in a Phase II study to...
08:00 , Jan 6, 2014 |  BC Week In Review  |  Financial News

Metabolon completes venture financing

Metabolon Inc. , Durham, N.C.   Business: Supply/Service, Diagnostic   Date completed: 1/3/14   Type: Venture financing   Raised: $15 million   Investors: Camden Partners; Sumitomo; Aurora Funds; Harris & Harris Group; Syngenta; Fletcher Spaght...
00:53 , Jan 4, 2014 |  BC Extra  |  Financial News

Metabolon raises $15 million in E round

Metabolomics company Metabolon Inc. (Durham, N.C.) raised $15 million in a series E round led by new investor Camden Partners. New investor Sumitomo Corp. (Tokyo:8053) also participated, along with existing investors Aurora Funds; Harris &...
07:00 , Sep 9, 2013 |  BioCentury  |  Finance

E round in the hand vs. IPO in the bush

The stars have yet to align for Argos Therapeutics Inc. 's pursuit of a public listing. An IPO attempt last year fizzled in poor market conditions, and when the window opened several months ago, the...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Financial News

Argos completes venture financing

Argos Therapeutics Inc. , Durham, N.C.   Business: Cancer, Infectious   Date completed: 8/26/13   Type: Venture financing   Raised: $42.5 million   Investors: Pharmstandard International; Green Cross; Forbion Capital Partners; TVM Capital; Lumira Capital;...
00:07 , Aug 27, 2013 |  BC Extra  |  Financial News

Argos raises $42.5M in series E

Argos Therapeutics Inc. (Durham, N.C.) raised $42.5 million in a series E round led by new investor Pharmstandard International S.A., a holding company of Pharmstandard OJSC (RTS:PHST; LSE:PHST). New investor Green Cross Corp. (KSE:006280) also...
08:00 , Dec 24, 2012 |  BC Week In Review  |  Financial News

Regado Biosciences completes venture financing

Regado Biosciences Inc. , Basking Ridge, N.J.   Business: Cardiovascular   Date completed: 12/19/12   Type: Venture financing   Raised: $51 million   Investors: Rusnano; Baxter Ventures; Edmond de Rothschild Investment Partners; Domain Associates; Quaker...
01:32 , Dec 20, 2012 |  BC Extra  |  Financial News

Regado raises $51 million in E round

Regado Biosciences Inc. (Basking Ridge, N.J.) raised $51 million in a series E round led by new investor Rusnano. New investor Baxter Ventures joined existing investors Edmond de Rothschild; Domain Associates; Quaker Partners; Aurora Funds;...
08:00 , Nov 12, 2012 |  BC Week In Review  |  Financial News

Cardioxyl completes venture financing

Cardioxyl Pharmaceuticals Inc. , Chapel Hill, N.C.   Business: Cardiovascular   Date completed: 11/5/12   Type: Venture financing   Raised: $28.1 million   Investors: OrbiMed Advisors; Osage Partners; New Enterprise Associates; Aurora Funds  ...